Pfizer’s board of directors elected CEO Ian Read chairman, succeeding George Lorch in that post. The board also elected two new directors: Dr. Marc Tessier-Lavigne, PhD, president of The Rockefeller University and a former chief scientific officer at Genentech; and Dr. Helen Hobbs, a prominent geneticist who works as an investigator for the Howard Hughes Medical Institute and professor at the University of Texas Southwestern Medical Center. .